Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 12 of 18
Next
>>
>
276 to 300 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-549	Everolimus	3	72	sigmoid	flat	BT549 everolimus 0 3 72	8	1.587	59.5	0.533	0.425	1e-05	0.395	0.1	0.702	0.0264	NA	Inf	0.656	0.685	0.0	0.656	0.01	0.48	0.141	0.685
Hs 578T	AZD-6482	3		sigmoid	sigmoid	Hs578T AZD6482 3	8	2.832	6.09	0.667	0.0547	24.1	-1.0	0.799	0.989	1.5e-06	NA	5.12	0.597	0.93	5.12	0.0	0.861	0.985	3.33e-06	NA
HCC70	AS605240	2	72	sigmoid	sigmoid	HCC70 AS-605240 0 2 72	8	1.771	6.13	0.558	0.126	1.21	0.339	0.698	0.981	7.24e-06	NA	785.0	0.643	0.894	0.946	0.496	0.708	0.978	1.04e-05	NA
Hs 578T	AZD-6482	2		sigmoid	sigmoid	Hs578T AZD6482 2	8	2.508	6.35	0.602	0.121	74.8	-1.0	0.445	0.998	1.12e-08	NA	6.4	0.573	0.86	6.4	0.0	0.475	0.996	6.36e-08	NA
Hs 578T	AS605240	3		sigmoid	sigmoid	Hs578T AS-605240 3	8	2.856	63.8	0.588	0.0965	0.826	0.494	1.03	0.983	4.89e-06	NA	5.75	0.518	0.879	0.552	0.465	1.14	0.981	6.87e-06	NA
BT-549	PIK-93	2	72	sigmoid	sigmoid	BT549 PIK-93 0 2 72	8	1.983	7.03	0.687	0.0641	29.9	-1.0	0.759	0.956	8.81e-05	NA	10.4	0.713	0.939	10.4	0.0	0.788	0.949	0.000136	NA
HCC38	Pictilisib	1	72	sigmoid	sigmoid	HCC38 pictilisib 0 1 72	8	1.759	7.16	0.562	0.125	1.04	0.377	0.725	0.992	5.12e-07	NA	Inf	0.647	0.896	0.797	0.529	0.742	0.992	5.77e-07	NA
HCC38	MK2206	3	72	sigmoid	sigmoid	HCC38 MK-2206 0 3 72	8	1.445	71.7	0.728	0.123	320.0	-0.26	0.28	0.854	0.0031	NA	Inf	0.81	0.912	4.3	0.61	0.332	0.834	0.00461	NA
HCC1806	MK2206	3	72	sigmoid	sigmoid	HCC1806 MK-2206 0 3 72	8	3.199	74.1	0.843	0.0434	320.0	-0.491	0.468	0.981	6.96e-06	NA	Inf	0.769	0.934	4.46	0.507	0.566	0.976	1.46e-05	NA
HCC38	Everolimus	2	72	sigmoid	flat	HCC38 everolimus 0 2 72	8	2.170	8323.0	0.58	0.376	0.000127	0.417	0.1	0.688	0.0303	NA	Inf	0.6	0.637	0.0	0.6	0.01	0.509	0.119	0.637
HCC38	Sirolimus	3	72	sigmoid	sigmoid	HCC38 rapamycin 0 3 72	8	1.420	86.3	0.535	0.403	0.000236	0.361	0.1	0.901	0.000982	NA	75575.0	0.687	0.727	0.000198	0.569	0.1	0.889	0.00136	NA
BT-549	AZD-6482	3	72	sigmoid	sigmoid	BT549 AZD6482 0 3 72	8	1.744	8.87	0.616	0.0979	2.2	0.324	0.749	0.993	2.93e-07	NA	115.0	0.69	0.918	1.91	0.476	0.744	0.993	4.19e-07	NA
BT-549	AZD-6482	2	72	sigmoid	sigmoid	BT549 AZD6482 0 2 72	8	1.973	9.15	0.635	0.112	120.0	-1.0	0.426	0.951	0.000115	NA	19.4	0.672	0.895	19.4	0.0	0.437	0.946	0.000154	NA
BT-549	TGX221	3	72	sigmoid	sigmoid	BT549 TGX-221 0 3 72	8	1.768	93790.0	0.805	0.0889	320.0	0.356	0.22	0.707	0.0251	NA	49050766.0	0.834	0.923	320.0	0.461	0.214	0.703	0.0263	NA
HCC1806	WYE-125132	3	72	sigmoid	sigmoid	HCC1806 WYE-132 0 3 72	8	3.242	Inf	0.531	0.255	0.0458	0.517	0.885	0.997	3.48e-08	NA	0.226	0.42	0.663	0.0335	0.402	0.855	0.996	8.79e-08	NA
HCC1806	XL147	1	72	flat	flat	HCC1806 pilaralisib 0 1 72	8	2.732	Inf	1.02	0.00101	0.0	1.02	0.01	-4.53e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0
HCC1806	XL147	2	72	flat	flat	HCC1806 pilaralisib 0 2 72	8	2.817	Inf	1.02	0.000975	0.0	1.02	0.01	-4.46e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000109	1.0	1.0
HCC1806	XL147	3	72	flat	flat	HCC1806 pilaralisib 0 3 72	8	3.185	Inf	1.02	0.000871	0.0	1.02	0.01	-2.12e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0
HCC1806	ZSTK474	1	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 1 72	8	2.709	Inf	0.602	0.037	1.17	0.599	4.88	0.99	1.12e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
HCC1806	ZSTK474	2	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 2 72	8	2.794	Inf	0.613	0.036	1.16	0.61	5.0	0.99	1.1e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
HCC1806	ZSTK474	3	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 3 72	8	3.162	Inf	0.654	0.0322	1.18	0.65	4.68	0.99	1.03e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
BT-549	AS605240	3	72	sigmoid	sigmoid	BT549 AS-605240 0 3 72	8	1.796	Inf	0.863	0.066	4.3	0.721	0.307	0.896	0.00112	NA	Inf	0.881	0.942	4.35	0.756	0.302	0.894	0.00118	NA
BT-549	AS605240	2	72	flat	flat	BT549 AS-605240 0 2 72	8	1.961	Inf	0.91	0.0479	0.0	0.91	0.01	0.414	0.201	0.949	Inf	0.914	0.954	0.0	0.914	0.01	0.418	0.197	0.951
BT-549	AS605240	1	72	sigmoid	sigmoid	BT549 AS-605240 0 1 72	8	1.804	Inf	0.893	0.0436	4.49	0.778	0.375	0.862	0.00261	NA	Inf	0.905	0.961	4.52	0.804	0.371	0.861	0.00267	NA
BT-20	XL147	3	72	flat	flat	BT20 pilaralisib 0 3 72	8	2.647	Inf	0.755	0.102	0.0	0.755	0.01	0.0679	0.81	0.885	Inf	0.708	0.871	0.0	0.708	0.01	0.0505	0.856	0.857

|<
<<
Previous
Page 12 of 18
Next
>>
>
276 to 300 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)